Atara Biotherapeutics, Inc. is a biotechnology company specializing in allogeneic T-cell immunotherapies aimed at treating patients with cancer and autoimmune diseases. Founded in 2012 and headquartered in Thousand Oaks, California, Atara leverages the natural biology of T cells to develop transformative therapies. The company's mission is to harness the power of the immune system to deliver innovative treatments that can change patients' lives worldwide.
Atara's strategic focus centers on its proprietary Epstein-Barr virus (EBV) T-cell platform, which utilizes allogeneic (donor-derived) T cells to target and destroy disease-causing cells. This platform is designed to be versatile, allowing for the development of therapies that can be rapidly delivered to patients from inventory. The company is pioneering in the field, being the first to receive approval for an allogeneic T-cell immunotherapy.
In 2024, Atara reported a significant increase in revenue, reaching $128.9 million, marking a 1,404% growth compared to the previous year. This surge was primarily attributed to the commercialization of their lead product, Ebvallo (tabelecleucel), in Europe. The company's market capitalization as of October 29, 2024, stood at $50.3 million.
Atara's pipeline includes several key candidates:
- Ebvallo (tabelecleucel): An allogeneic T-cell immunotherapy approved in Europe for the treatment of EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD).
- ATA3219: An allogeneic CAR T therapy targeting CD19, currently in preclinical development for B-cell malignancies.
- ATA188: A T-cell immunotherapy targeting EBV in multiple sclerosis, in preclinical stages.
- ATA3431: A preclinical program focusing on dual CD19/CD20 targeting in B-cell malignancies.
Atara's EBV T-cell platform is a cornerstone of its innovation, utilizing allogeneic T cells without the need for T-cell receptor or human leukocyte antigen gene editing. This approach enables the development of off-the-shelf immunotherapies that can be rapidly delivered to patients. The platform's versatility allows for applications across a wide range of disease-causing viral and non-viral targets.
The leadership team at Atara includes:
- Cokey Nguyen, Ph.D.: President and Chief Executive Officer.
- Yanina Grant-Huerta: Chief Accounting Officer.
- Jim Sesic: Senior Vice President, Regulatory Affairs.
- John Chao: Head of Legal.
The Board of Directors is chaired by Pascal Touchon, with Carol G. Gallagher, Pharm.D., serving as the Independent Lead Director.
In 2023, Atara sold its marketing rights to Ebvallo in North America, Asia Pacific, and Latin America to Pierre Fabre Laboratories. Additionally, in December 2022, the company entered into a royalty interest financing agreement worth $31 million with HealthCare Royalty for Ebvallo in Europe and other territories covered by Atara’s commercialization agreement with Pierre Fabre.
The biotechnology sector is highly competitive, with Atara facing competition from major players such as Amgen, Gilead Sciences, and Novartis, all of whom have significant research and development budgets. The presence of numerous players in this market leads to heightened competition for Atara Biotherapeutics.
Atara has established strategic collaborations to enhance its research and development capabilities:
- Memorial Sloan Kettering Cancer Center: A license agreement for development and manufacturing.
- QIMR Berghofer: An exclusive license to develop and commercialize immunotherapies utilizing technology developed by Dr. Rajiv Khanna.
- Pierre Fabre: A strategic collaboration to commercialize tab-cel in Europe, the Middle East, Africa, and other select markets.
Atara's strategic roadmap includes advancing its pipeline candidates through clinical development, expanding its technological platform to address a broader range of diseases, and strengthening its market position through strategic partnerships. The company's focus on allogeneic T-cell therapies positions it to address unmet medical needs in oncology and autoimmune diseases effectively.
For more information, visit Atara Biotherapeutics' official website at www.atarabio.com.
